AstraZeneca Results Presentation Deck

Late-stage pipeline events over the next 18 months News flow picks up; Phase III readouts increase into H2'21 Regulatory decision Regulatory submission acceptance and/or submission Key Phase III data readout H2 2021 Forxiga - CKD (EU, JP) roxadustat - anaemia in CKD (US) anifrolumab - lupus (SLE) (US, EU, JP) Imfinzi + tremelimumab - NSCLC (1L) (POSEIDON) Lynparza - adjuvant breast cancer Lynparza - prostate cancer (1L, castration-resistant) Enhertu - breast cancer (2L, HER2+) Calquence - CLL (R/R) (ELEVATE-RR) COVID-19 vaccine - COVID-19 (US) AZD7442 - SARS-CoV-2 Imfinzi - unresectable, Stage III NSCLC (PACIFIC-2) Imfinzi +/-treme - liver cancer (1L) Lynparza - prostate cancer (1L, castration-resistant) Enhertu - breast cancer (2L, HER2+)¹ PT027-asthma AZD7442 - SARS-CoV-2 Status as of 29 July 2021. 1. Based on a planned interim analysis as communicated by Daiichi Sankyo in Q2 of their fiscal year 2021. 34 H1 2022 Brilique - stroke (THALES) (EU, CN) Forxiga - CKD (CN) Fasenra - nasal polyps (US) tezepelumab - asthma (US, EU, JP) Imfinzi - unresectable, Stage III NSCLC (PACIFIC-2) Imfinzi +/-treme - liver cancer (1L) Enhertu - breast cancer (HER2 low) Calquence - CLL (CN) Koselugo - NF1 (JP, CN) Farxiga - HF (HFpEF) PT027 - asthma (US) nirsevimab - RSV Imfinzi - NSCLC (1L) (PEARL) Imfinzi - cervical cancer Enhertu - breast cancer (HER2 low) Farxiga - HF (HFpEF) roxadustat - anaemia in myelodysplastic syndrome H2 2022 Imfinzi - NSCLC (1L) (PEARL) Imfinzi - cervical cancer Imfinzi - biliary tract cancer Enhertu - breast cancer (3L, HER2+) (Phase III) roxadustat - anaemia in myelodysplastic syndrome Fasenra- eosinophilic oesophagitis Imfinzi - limited-stage SCLC Imfinzi - liver cancer (locoregional) (EMERALD-1) Imfinzi - biliary tract cancer Enhertu - breast cancer (3L, HER2+) (Phase III) Fasenra - hyper-eosinophilic syndrome Fasenra- eosinophilic oesophagitis B

View entire presentation